Solvonis Therapeutics plc (SVNS), an emerging biopharmaceutical company developing novel medicines for high-burden central nervous system (CNS) disorders, announced that its novel AI-discovered compound, SVN-015, targeting methamphetamine and cocaine use disorders,
